143 related articles for article (PubMed ID: 32002359)
41. Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance.
Punfa W; Suzuki S; Pitchakarn P; Yodkeeree S; Naiki T; Takahashi S; Limtrakul P
Asian Pac J Cancer Prev; 2014; 15(21):9249-58. PubMed ID: 25422208
[TBL] [Abstract][Full Text] [Related]
42. Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management.
Abhang A; Katari O; Ghadi R; Chaudhari D; Jain S
Drug Deliv Transl Res; 2024 Feb; 14(2):510-523. PubMed ID: 37605040
[TBL] [Abstract][Full Text] [Related]
43. [Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles for intraarterial local drug delivery: preparation, characterization, and in vitro/in vivo release].
Miao LF; Yang J; Huang CL; Song CX; Zeng YJ; Chen LF; Zhu WL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):491-7. PubMed ID: 18795627
[TBL] [Abstract][Full Text] [Related]
44. Efficient delivery of antitumor drug to the nuclei of tumor cells by amphiphilic biodegradable poly(L-aspartic acid-co-lactic acid)/DPPE co-polymer nanoparticles.
Han S; Liu Y; Nie X; Xu Q; Jiao F; Li W; Zhao Y; Wu Y; Chen C
Small; 2012 May; 8(10):1596-606. PubMed ID: 22411637
[TBL] [Abstract][Full Text] [Related]
45. Development of Nanoparticles for Drug Delivery to Brain Tumor: The Effect of Surface Materials on Penetration Into Brain Tissue.
Lei C; Davoodi P; Zhan W; Chow PK; Wang CH
J Pharm Sci; 2019 May; 108(5):1736-1745. PubMed ID: 30552956
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.
Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA
Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929
[TBL] [Abstract][Full Text] [Related]
47. Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery.
Song N; Liu W; Tu Q; Liu R; Zhang Y; Wang J
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):454-63. PubMed ID: 21719259
[TBL] [Abstract][Full Text] [Related]
48. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
49. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy.
Vivek R; Thangam R; NipunBabu V; Rejeeth C; Sivasubramanian S; Gunasekaran P; Muthuchelian K; Kannan S
ACS Appl Mater Interfaces; 2014 May; 6(9):6469-80. PubMed ID: 24780315
[TBL] [Abstract][Full Text] [Related]
50. Preparation, characterization and in vitro anticancer activity of paclitaxel conjugated magnetic nanoparticles.
Tarantash M; Nosrati H; Kheiri Manjili H; Baradar Khoshfetrat A
Drug Dev Ind Pharm; 2018 Nov; 44(11):1895-1903. PubMed ID: 30073853
[TBL] [Abstract][Full Text] [Related]
51. Preparation, characterization, and in vivo study of rhein-loaded poly(lactic-co-glycolic acid) nanoparticles for oral delivery.
Yuan Z; Gu X
Drug Des Devel Ther; 2015; 9():2301-9. PubMed ID: 25960633
[TBL] [Abstract][Full Text] [Related]
52. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
53.
Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Meléndez-Alafort L; Trujillo-Nolasco M; Ocampo-García B
Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110043. PubMed ID: 31546458
[TBL] [Abstract][Full Text] [Related]
54. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.
Wang H; Liu J; Tao S; Chai G; Wang J; Hu FQ; Yuan H
Int J Nanomedicine; 2015; 10():5671-85. PubMed ID: 26388691
[TBL] [Abstract][Full Text] [Related]
55. The targeting properties of folate-conjugated Pluronic F127/poly (lactic-co-glycolic) nanoparticles.
Luo YY; Xiong XY; Cheng F; Gong YC; Li ZL; Li YP
Int J Biol Macromol; 2017 Dec; 105(Pt 1):711-719. PubMed ID: 28716749
[TBL] [Abstract][Full Text] [Related]
56. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
57. Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles.
Al-Humaidi RB; Fayed B; Shakartalla SB; Jagal J; Jayakumar MN; Al Shareef ZM; Sharif SI; Noreddin A; Semreen MH; Omar HA; Haider M; Soliman SSM
Life Sci; 2022 Sep; 305():120778. PubMed ID: 35792181
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.
Shah N; Chaudhari K; Dantuluri P; Murthy RS; Das S
J Drug Target; 2009 Aug; 17(7):533-42. PubMed ID: 19530913
[TBL] [Abstract][Full Text] [Related]
59. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
60. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
